Actuate Therapeutics (NASDAQ:ACTU - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for Actuate Therapeutics in a note issued to investors on Monday, March 17th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings of ($0.26) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. HC Wainwright also issued estimates for Actuate Therapeutics' Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.79) EPS and FY2026 earnings at ($0.98) EPS.
Actuate Therapeutics Stock Performance
Shares of ACTU traded down $0.24 on Wednesday, hitting $6.75. 17,713 shares of the stock traded hands, compared to its average volume of 45,032. The stock's 50 day moving average is $8.08 and its two-hundred day moving average is $8.05. Actuate Therapeutics has a 1 year low of $5.51 and a 1 year high of $11.73.
Hedge Funds Weigh In On Actuate Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the company. OMERS ADMINISTRATION Corp purchased a new position in shares of Actuate Therapeutics during the 4th quarter worth about $84,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Actuate Therapeutics during the 4th quarter worth about $130,000. Voss Capital LP purchased a new position in shares of Actuate Therapeutics during the 4th quarter worth about $440,000. Envestnet Asset Management Inc. purchased a new position in shares of Actuate Therapeutics during the 4th quarter worth about $83,000. Finally, BIOS Capital Management LP purchased a new position in shares of Actuate Therapeutics during the 4th quarter worth about $78,753,000.
About Actuate Therapeutics
(
Get Free Report)
Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
Recommended Stories
Before you consider Actuate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Actuate Therapeutics wasn't on the list.
While Actuate Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
